DOXORUBICINE ACCORD 2 mg/ml

DRUG7 trials

Sponsors

French Innovative Leukemia Organization, Lysarc, Seagen Inc., Institut Bergonie

Conditions

Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitonealClassical Hodgkin LymphomaPatients with previously untreated Richter’s syndrome (RS)Peripheral T-cell LymphomaRelapsed or Refractory Marginal Zone LymphomaResectabledefined as the transformation of chronic lymphocytic leukemia (CLL) into high-grade lymphoma of diffuse large B-cell lymphoma (DLBCL) histology.

Phase 2

FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY

RecruitingCTIS2022-501554-11-00

French Innovative Leukemia Organizationdefined as the transformation of chronic lymphocytic leukemia (CLL) into high-grade lymphoma of diffuse large B-cell lymphoma (DLBCL) histology., Patients with previously untreated Richter’s syndrome (RS)

Start: 2024-03-21Target: 40Updated: 2025-12-24

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

CompletedCTIS2023-503387-16-00

Seagen Inc.Classical Hodgkin Lymphoma

Start: 2021-07-13End: 2024-08-23Target: 22Updated: 2024-06-10

C5691004 _ A dual-cohort, open-label, phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression

CompletedCTIS2023-509155-14-00

Seagen Inc.Peripheral T-cell Lymphoma

Start: 2021-06-10End: 2026-01-05Target: 69Updated: 2026-01-16

TORNADO : RANDOMIZED PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY PLUS RETIFANLIMAB (INCMGA00012) IN PATIENTS WITH SELECTED RETROPERITONEAL SARCOMAS

Active, not recruitingCTIS2023-509498-21-00

Institut BergonieAdult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

Start: 2022-03-16Target: 66Updated: 2025-09-23

TRUST : BINTRAFUSP ALFA AND DOXORUBICIN HYDROCHLORIDE IN TREATING PATIENTS WITH ADVANCED SARCOMA

Active, not recruitingCTIS2023-509497-30-00

Institut BergonieAdult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

Start: 2022-02-21Target: 80Updated: 2025-12-12

Phase 3

MARSUN: Phase III, Multicenter, Open label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide versus investigator choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma

RecruitingCTIS2022-501810-77-00

LysarcRelapsed or Refractory Marginal Zone Lymphoma

Start: 2023-09-01Target: 260Updated: 2025-09-22

CIRSARC : PHASE III TRIAL INVESTIGATING BENEFIT OF INTENSIFIED PERI-OPERATIVE CHEMOTHERAPY WITHIN HIGH-RISK CINSARC PATIENTS WITH RESECTABLE SOFT-TISSUE SARCOMAS

RecruitingCTIS2023-509489-39-00

Institut Bergonienon-metastatic soft-tissue sarcoma (STS), Resectable

Start: 2019-02-05Target: 351Updated: 2025-12-22